Do analysts rate CLGN or TPST?

CollPlant Biotechnologies presently has a consensus target price of $12.00, indicating a potential upside of 3,270.79%. Given CollPlant Biotechnologies' higher possible upside, equities analysts clearly believe CollPlant Biotechnologies is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate CLGN or CMMB?

CollPlant Biotechnologies currently has a consensus price target of $12.00, suggesting a potential upside of 3,270.79%. Given CollPlant Biotechnologies' higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor CLGN or CMMB?

In the previous week, CollPlant Biotechnologies had 5 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 9 mentions for CollPlant Biotechnologies and 4 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.93 beat CollPlant Biotechnologies' score of 0.27 indicating that Chemomab Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLGN or PLUR?

In the previous week, CollPlant Biotechnologies had 5 more articles in the media than Pluri. MarketBeat recorded 9 mentions for CollPlant Biotechnologies and 4 mentions for Pluri. Pluri's average media sentiment score of 0.81 beat CollPlant Biotechnologies' score of 0.27 indicating that Pluri is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pluri 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLGN or BCDA?

In the previous week, CollPlant Biotechnologies had 7 more articles in the media than BioCardia. MarketBeat recorded 9 mentions for CollPlant Biotechnologies and 2 mentions for BioCardia. BioCardia's average media sentiment score of 0.47 beat CollPlant Biotechnologies' score of 0.27 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CLGN or BIVI?

In the previous week, BioVie had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 10 mentions for BioVie and 9 mentions for CollPlant Biotechnologies. BioVie's average media sentiment score of 0.75 beat CollPlant Biotechnologies' score of 0.27 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioVie 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CollPlant Biotechnologies (CLGN) Competitors

$0.36 -0.03 (-8.22%)

As of 12:08 PM Eastern

Compare

CLGN vs. TPST, CMMB, PLUR, BCDA, and BIVI

Should you buy CollPlant Biotechnologies stock or one of its competitors? CollPlant Biotechnologies's main competitors and comparable companies include Tempest Therapeutics (TPST), Chemomab Therapeutics (CMMB), Pluri (PLUR), BioCardia (BCDA), and BioVie (BIVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CollPlant Biotechnologies compare to Tempest Therapeutics?

CollPlant Biotechnologies (NASDAQ:CLGN) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tempest Therapeutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Tempest Therapeutics	N/A	-576.56%	-134.99%

CollPlant Biotechnologies has higher revenue and earnings than Tempest Therapeutics. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.17	-$11.49M	-$1.45	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

In the previous week, CollPlant Biotechnologies had 8 more articles in the media than Tempest Therapeutics. MarketBeat recorded 9 mentions for CollPlant Biotechnologies and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.89 beat CollPlant Biotechnologies' score of 0.27 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
Tempest Therapeutics	Very Positive

CollPlant Biotechnologies has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.72, suggesting that its share price is 272% less volatile than the broader market.

CollPlant Biotechnologies presently has a consensus target price of $12.00, indicating a potential upside of 3,270.79%. Given CollPlant Biotechnologies' higher possible upside, equities analysts clearly believe CollPlant Biotechnologies is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

CollPlant Biotechnologies beats Tempest Therapeutics on 7 of the 13 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Chemomab Therapeutics?

CollPlant Biotechnologies (NASDAQ:CLGN) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Chemomab Therapeutics has lower revenue, but higher earnings than CollPlant Biotechnologies. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.17	-$11.49M	-$1.45	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A

CollPlant Biotechnologies has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

In the previous week, CollPlant Biotechnologies had 5 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 9 mentions for CollPlant Biotechnologies and 4 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.93 beat CollPlant Biotechnologies' score of 0.27 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Chemomab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Chemomab Therapeutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Chemomab Therapeutics' return on equity of -92.14% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Chemomab Therapeutics	N/A	-92.14%	-82.05%

CollPlant Biotechnologies currently has a consensus price target of $12.00, suggesting a potential upside of 3,270.79%. Given CollPlant Biotechnologies' higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Chemomab Therapeutics beats CollPlant Biotechnologies on 7 of the 13 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Pluri?

CollPlant Biotechnologies (NASDAQ:CLGN) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

CollPlant Biotechnologies has a net margin of -683.68% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Pluri	-2,162.08%	N/A	-106.59%

CollPlant Biotechnologies has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Pluri has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

CollPlant Biotechnologies has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.17	-$11.49M	-$1.45	N/A
Pluri	$1.34M	11.99	-$22.58M	-$4.53	N/A

CollPlant Biotechnologies currently has a consensus target price of $12.00, indicating a potential upside of 3,270.79%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, research analysts clearly believe CollPlant Biotechnologies is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CollPlant Biotechnologies had 5 more articles in the media than Pluri. MarketBeat recorded 9 mentions for CollPlant Biotechnologies and 4 mentions for Pluri. Pluri's average media sentiment score of 0.81 beat CollPlant Biotechnologies' score of 0.27 indicating that Pluri is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pluri	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CollPlant Biotechnologies beats Pluri on 10 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to BioCardia?

CollPlant Biotechnologies (NASDAQ:CLGN) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

BioCardia has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
BioCardia	N/A	-569.36%	-183.15%

BioCardia has lower revenue, but higher earnings than CollPlant Biotechnologies. BioCardia is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.17	-$11.49M	-$1.45	N/A
BioCardia	$60K	280.09	-$8.23M	-$0.64	N/A

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CollPlant Biotechnologies has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

CollPlant Biotechnologies presently has a consensus target price of $12.00, suggesting a potential upside of 3,270.79%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,152.25%. Given CollPlant Biotechnologies' higher probable upside, equities research analysts plainly believe CollPlant Biotechnologies is more favorable than BioCardia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CollPlant Biotechnologies had 7 more articles in the media than BioCardia. MarketBeat recorded 9 mentions for CollPlant Biotechnologies and 2 mentions for BioCardia. BioCardia's average media sentiment score of 0.47 beat CollPlant Biotechnologies' score of 0.27 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCardia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CollPlant Biotechnologies and BioCardia tied by winning 8 of the 16 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to BioVie?

CollPlant Biotechnologies (NASDAQ:CLGN) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 0.9% of BioVie shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CollPlant Biotechnologies has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.17	-$11.49M	-$1.45	N/A
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A

CollPlant Biotechnologies currently has a consensus target price of $12.00, suggesting a potential upside of 3,270.79%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, research analysts plainly believe CollPlant Biotechnologies is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioVie had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 10 mentions for BioVie and 9 mentions for CollPlant Biotechnologies. BioVie's average media sentiment score of 0.75 beat CollPlant Biotechnologies' score of 0.27 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioVie	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CollPlant Biotechnologies has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, BioVie has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

BioVie has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. BioVie's return on equity of -126.02% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
BioVie	N/A	-126.02%	-108.88%

Summary

CollPlant Biotechnologies beats BioVie on 9 of the 14 factors compared between the two stocks.

Get CollPlant Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLGN vs. The Competition

Export

Metric	CollPlant Biotechnologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.14M	$3.95B	$7.15B	$12.76B
Dividend Yield	N/A	3.61%	2.54%	10.96%
P/E Ratio	-0.25	11.84	272.37	25.17
Price / Sales	2.17	1,323.13	618.45	97.60
Price / Cash	N/A	44.06	28.78	36.03
Price / Book	0.74	16.86	11.04	6.27
Net Income	-$11.49M	-$22.72M	$3.47B	$348.97M
7 Day Performance	22.76%	-2.55%	-1.52%	-1.95%
1 Month Performance	23.18%	11.30%	7.32%	3.46%
1 Year Performance	-86.41%	54.55%	23.96%	14.18%

CollPlant Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLGN CollPlant Biotechnologies	2.1882 of 5 stars	$0.36 -8.2%	$12.00 +3,270.8%	-85.2%	$5.14M	$2.37M	N/A	70	News Coverage Gap Down High Trading Volume
TPST Tempest Therapeutics	1.3458 of 5 stars	$1.10 -1.3%	N/A	-89.0%	$18.13M	N/A	N/A	20	Positive News
CMMB Chemomab Therapeutics	1.2369 of 5 stars	$2.38 +3.5%	$25.00 +950.4%	-13.4%	$17.39M	N/A	N/A	20	News Coverage
PLUR Pluri	0.9115 of 5 stars	$1.61 +2.9%	N/A	-72.1%	$17.32M	$1.34M	N/A	150	Gap Down
BCDA BioCardia	3.9771 of 5 stars	$1.12 -0.9%	$25.00 +2,132.1%	-42.3%	$16.96M	$60K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLGN) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. TPST, CMMB, PLUR, BCDA, and BIVI

How does CollPlant Biotechnologies compare to Tempest Therapeutics?

Summary

How does CollPlant Biotechnologies compare to Chemomab Therapeutics?

Summary

How does CollPlant Biotechnologies compare to Pluri?

Summary

How does CollPlant Biotechnologies compare to BioCardia?

Summary

How does CollPlant Biotechnologies compare to BioVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. TPST, CMMB, PLUR, BCDA, and BIVI

How does CollPlant Biotechnologies compare to Tempest Therapeutics?

Do institutionals and insiders believe in CLGN or TPST?

Is CLGN or TPST more profitable?

Which has better earnings and valuation, CLGN or TPST?

Does the media favor CLGN or TPST?

Which has more volatility & risk, CLGN or TPST?

Do analysts rate CLGN or TPST?

Summary

How does CollPlant Biotechnologies compare to Chemomab Therapeutics?

Which has stronger valuation & earnings, CLGN or CMMB?

Which has more risk & volatility, CLGN or CMMB?

Does the media favor CLGN or CMMB?

Is CLGN or CMMB more profitable?

Do analysts rate CLGN or CMMB?

Do institutionals and insiders hold more shares of CLGN or CMMB?

Summary

How does CollPlant Biotechnologies compare to Pluri?

Is CLGN or PLUR more profitable?

Which has more volatility & risk, CLGN or PLUR?

Which has preferable earnings & valuation, CLGN or PLUR?

Do analysts rate CLGN or PLUR?

Do institutionals and insiders have more ownership in CLGN or PLUR?

Does the media prefer CLGN or PLUR?

Summary

How does CollPlant Biotechnologies compare to BioCardia?

Is CLGN or BCDA more profitable?

Which has higher earnings & valuation, CLGN or BCDA?

Do insiders and institutionals have more ownership in CLGN or BCDA?

Which has more volatility & risk, CLGN or BCDA?

Do analysts recommend CLGN or BCDA?

Does the media favor CLGN or BCDA?

Summary

How does CollPlant Biotechnologies compare to BioVie?

Do insiders and institutionals hold more shares of CLGN or BIVI?

Which has stronger earnings and valuation, CLGN or BIVI?

Do analysts rate CLGN or BIVI?

Does the media favor CLGN or BIVI?

Which has more volatility and risk, CLGN or BIVI?

Is CLGN or BIVI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools